$Chimerix(CMRX.US)$ONC206 is a second generation ClpP agonist and DRD2 antagonist that has demonstrated monotherapy anti-cancer activity in pre-clinical models in primary CNS tumors and solid tumors outside of the CNS. Phase I dose escalation trials continue at the National Institutes of Health (NIH) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) in adult and pediatric CNS tumor patients, respectively. The dose escalation trials are currently dosing at a...
Mike Andriole, CEO of Chimerix, welcomes Lisa Decker for her scientific expertise, oncology drug development and business development experience. He appreciates her as an asset to Chimerix as the company advances its pipeline towards commercialization.
Chimerix's CEO is confident in Michelle's potential to push the company into its next growth phase. Michelle is keen on opportunities for Chimerix's growth, particularly for the imipridone pipeline, and aims to help turn Chimerix into a top oncology firm.
The inclusion of Thomas Riga in the Chimerix leadership team is expected to boost the company’s operations given his extensive experience in oncology commercialization and corporate business development, especially as the company gears towards commercializing its clinical-stage development program, ONC201.
$Chimerix(CMRX.US)$ This is all I need to hold and/or buy more on dips "..Turning to clinical outcomes. The survival of H3 K27-mutant glioma patients who received ONC201 in the frontline setting following radiotherapy, which I'll notice the same setting of the ACTION trial was reported as 21.7 months from diagnosis in contrast to 12 months for patients who did not receive ONC201. Favorable survival outcomes among ONC201 treated patients were consistently observed across a variety of sensitivity ...
Chimerix股票討論區
Phase I dose escalation trials continue at the National Institutes of Health (NIH) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) in adult and pediatric CNS tumor patients, respectively. The dose escalation trials are currently dosing at a...
This is all I need to hold and/or buy more on dips
"..Turning to clinical outcomes. The survival of H3 K27-mutant glioma patients who received ONC201 in the frontline setting following radiotherapy, which I'll notice the same setting of the ACTION trial was reported as 21.7 months from diagnosis in contrast to 12 months for patients who did not receive ONC201. Favorable survival outcomes among ONC201 treated patients were consistently observed across a variety of sensitivity ...
德開始報道於 Chimerix Inc (納斯達克股票代碼:CMRX)的評級爲 “跑贏大盤”。Chimerix的目標價格定爲7.00美元。Chimerix在第一季度的收入爲0.24美元,而去年同期爲0.28美元。目前,該股創下52周高點2.89美元,創52周低點1.09美元。Chimerix在上一個交易期結束時收於1.40美元。
暫無評論